# Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

> **NCT00310713** · PHASE4 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 33 (actual)

## Conditions studied

- Prevention of Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal C conjugate vaccine

## Key facts

- **NCT ID:** NCT00310713
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310713, "Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00310713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*